Stock A328130 LUNIT INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Lunit Inc.

Equities

A328130

KR7328130000

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
55,000 KRW +7.63% Intraday chart for Lunit Inc. -3.34% -32.84%
May. 24 Lunit to Showcase 7 Studies at Asco 2024, Including Ai Innovations in Her2 Quantification, and Multimodal Predictive Models for Immunotherapy Response CI
May. 23 Lunit Acquires New Zealand's Volpara Health Technologies MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lunit to Showcase 7 Studies at Asco 2024, Including Ai Innovations in Her2 Quantification, and Multimodal Predictive Models for Immunotherapy Response
CI
Lunit Acquires New Zealand's Volpara Health Technologies
MT
Lunit Inc. completed the acquisition of Volpara Health Technologies Limited from Harbour Asset Management Limited and others.
CI
Volpara to Delist After Court Approves Acquisition by Lunit
MT
Lunit Wins Shareholder Approval for Volpara Health Takeover
MT
Volpara Health Technologies Secures Approval for Lunit’s Proposed Takeover
MT
Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals
CI
Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients
AQ
Lunit Announces Publication of New Study Featuring Lunit SCOPE IO
CI
Lunit Announces Two Commercial Deals Signal its Expansion in Europe
CI
Lunit SCOPE AI Enhances Pathologist Concordance and Accuracy in HER2, ER, and PR Assessment, New Study in Breast Cancer Research
AQ
Lunit Inc. Receives Two Supply Contracts That Mark Its Strategic Expansion into the East and Southeast Asian Region
CI
Lunit Presents Seven Study Results at ECR 2024, Showcasing AI's Robust Performance in Diverse Clinical Settings
AQ
New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy across Diverse Tumors, published in the JITC
AQ
Lunit INSIGHT CXR Excels in Long Nodule Detection, Exceptional Performance in Head-to-Head Study published in Radiology
AQ
Lunit Announces Three-Year Supply Contract with Samsung Electronics
CI
GC Cell Signs Agreement with Lunit for AI-Powered Cancer Treatment
MT
Lunit to Acquire Volpara, Scheme Implementation Agreement Signed
AQ
Lunit to Take Over Volpara Health; Lunit Shares Decline 4%
MT
Lunit Inc. agreed to acquire Volpara Health Technologies Limited from Harbour Asset Management Limited and others for AUD 300 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A328130 Stock
  4. News Lunit Inc.